Nestlé S.A. (SWX:NESN) is discussing a potential sale of its peanut allergy medicine to Swiss health-care group Stallergenes Greer Ltd, people with knowledge of the matter said. Stallergenes has been holding talks with Nestlé about a possible deal for the Palforzia treatment, the people said, asking not to be identified discussing confidential information.